Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis

✍ Scribed by Richeldi, Luca; du Bois, Roland M.; Raghu, Ganesh; Azuma, Arata; Brown, Kevin K.; Costabel, Ulrich; Cottin, Vincent; Flaherty, Kevin R.; Hansell, David M.; Inoue, Yoshikazu; Kim, Dong Soon; Kolb, Martin; Nicholson, Andrew G.; Noble, Paul W.; Selman, Moisés; Taniguchi, Hiroyuki; Brun, Michèle; Le Maulf, Florence; Girard, Mannaïg; Stowasser, Susanne; Schlenker-Herceg, Rozsa; Disse, Bernd; Collard, Harold R.

• Book ID: 124064057
• Publisher: Massachusetts Medical Society
• Year: 2014
• Tongue: English
• Weight: 565 KB
• Volume: 370
• Category: Article
• ISSN: 0096-6762
• DOI: 10.1056/NEJMoa1402584

✦ Synopsis

In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintedanib was frequently associated with diarrhea, which led to discontinuation of the study medication in less than 5% of patients.